Cancer Clinical Trials

Cancer Clinical Trials

Cancer Clinical Trials

If you or someone you love is facing cancer, clinical trials may provide an alternative. Northwestern Medicine offers clinical studies right in your community for a wide variety of types and stages of cancer. These research studies are designed to test new ways to diagnose, treat and prevent cancer, as well as to manage symptoms and side effects of the disease.

Clinical trials have played an important role in the fight against cancer. They are the only scientific way to prove whether a new treatment works better than current treatments. Most of the approaches that doctors use to treat cancer today would never have become available without clinical trials.

Clinical Trials at Robert H. Lurie Comprehensive Cancer Center of Northwestern University

The Robert H. Lurie Comprehensive Cancer Center is typically involved in more than 300 clinical trials at a given time, covering a broad range of subjects. Some clinical trials study a drug, a medical device, or a new way of doing surgery. Others test new ways to prevent disease, diagnose cancer, improve quality of life, or help people with cancer manage difficult psychological and social issues.

If you have been diagnosed with cancer, feel that you are at high risk of being diagnosed with cancer, or if you are a survivor, ask your doctor if a clinical trial is right for you--now or possibly in the future.

To learn more, call 312.695.1102 or email cancertrials@northwestern.edu for personalized assistance. For Northern Suburbs call 312.695.1102.

Search Open Clinical Trials

Current Central DuPage Hospital, Delnor Hospital and Kishwaukee Hospital Cancer Clinical Trials

Currently, there are a wide variety of oncology clinical trials available through physicians on the medical staffs of Northwestern Medicine Central DuPage Hospital, Northwestern Medicine Delnor Hospital and Northwestern Medicine Kishwaukee Hospital. For ease of searching, the trials are sorted into the following categories:

  • Blood, Bone & Tissue
  • Brain
  • Breast
  • Cholangiocarcinoma
  • Colorectal
  • Gastrointestinal
  • Hepatocellular
  • Kidney
  • Lung
  • Pancreatic
  • Prostate
  • Rectal
  • Women's Reproductive System
  • Other Cancers

If you find a clinical trial that interests you, talk with your physician or call 630.933.6528. TTY for the hearing impaired 630.933.4833.


View Trials

Blood/Leukemia/Lymphoma

Study: Clinical Trial Center for Hematologic Malignancies, The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Center Partnership Tissue Acquisition.
Clinical Trial #: CASE5Z08
Principal Investigator: John Ayers, MD

Lymphoma

Study: A Phase 3, Randomized, Double-Blind Study of PF-05280586 versus Rituximab for the First-Line Treatment of Patient with CD20-POSITIVE, Low Tumor Burden, Follicular Lymphoma
Clinical Trial #: B3281006
Principal Investigator: Robert Bayer, MD

Learn more at Clinicaltrials.gov*

Multiple Myeloma

Study: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Clinical Trial #: E1A11
Principal Investigator: Robert Bayer, MD

Learn more at Clinicaltrials.gov*


Melanoma

Study: A Phase III Randomized Trial Comparing Physician/Patient Choice of High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Clinical Trial #: S1404
Principal Investigator: John Abad, MD

Learn more at Clinicaltrials.gov*


Melanoma

Study: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Clinical Trial #: EA6134
Principal Investigator: John Ayers, MD

Learn more at Clinicaltrials.gov*

Study: A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Clinical Trial #: OT-15-001
Principal Investigator: Sean Grimm, MD

Learn more at Clinicaltrials.gov*


Study: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)
Clinical Trial #: METIS EF-25
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov*


Study: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Clinical Trial #: NRG CC003
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov*


Study: A Randomized Phase III Trial Of Memantine And Whole-Brain Radiotherapy With Or Without Hippocampal Avoidance In Patients With Brain Metastases
Clinical Trial #: CC001
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov*


Study: Phase II Trial Of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
Clinical Trial #: A071401
Principal Investigator: Sean Grimm, MD

Learn more at Clinicaltrials.gov*


Study: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
Clinical Trial #: NRG-BN001
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov*


Study: A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas.
Clinical Trial #: NU 11C02
Principal Investigator: Vinai Gondi, MD

Learn more at Cancer.gov*


Study: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC#725085, Alliance IND# 15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM).
Clinical Trial #: Protocol A071101
Principal Investigator: Sean Grimm, MD

Learn more at Clinicaltrials.gov*


Study: A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme.
Clinical Trial #: Protocol 020221
Principal Investigator: Sean Grimm, MD

Learn more at Clinicaltrials.gov*


Study: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) to Reduce Cancer-Related Fatigue in Patients with High Grade Glioma.
Clinical Trial #: Protocol A221101
Principal Investigator: Sean Grimm, MD

Learn more at Clinicaltrials.gov*


Study: A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
Clinical Trial #: Protocol A071102
Principal Investigator: Sean Grimm, MD

Learn more at Cancer.gov*


Study: A Randomized, Placebo Controlled Phase 2b/3 Study of ABT 414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)
Clinical Trial #: RTOG 3508/AbbVie M13-813
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov*

Study: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study
Clinical Trial #: A011106
Principal Investigator: John Ayers, MD

Learn more at Clinicaltrials.gov*


Study: A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial
Clinical Trial #: A011502
Principal Investigator: John Ayers, MD

Learn more at Clinicaltrials.gov*


Study: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Clinical Trial #: A011401
Principal Investigator: John Ayers, MD

Learn more at Clinicaltrials.gov*


Study: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer
Clinical Trial #: BR003
Principal Investigator: Perry J. Menini, DO

Learn more at Clinicaltrials.gov*


Study: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and Her2/Neu Negative Breast Cancer.
Clinical Trial #: Protocol S1207
Principal Investigator: John Ayers, MD

Learn more at Clinicaltrials.gov*


Study: Phase II protocol of proton therapy for partial breast irradiation in early stage breast cancer.
Clinical Trial #: BRE007-12
Principal Investigator: Christy Kesslering, MD

Learn more at Clinicaltrials.gov*


Study: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy.
Clinical Trial #: Protocol A011202
Principal Investigator: Christy Kesslering, MD

Learn more at Clinicaltrials.gov*


Study: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes after Neoadjuvant Chemotherapy.
Clinical Trial #: NSABP-B51/RTOG-1304
Principal Investigator: Christy Kesslering, MD

Learn more at Clinicaltrials.gov*


Study: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer.
Clinical Trial #: E2112
Principal Investigator: Dragana Tomic, MD

Learn more at Cancer.gov*


Study: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.
Clinical Trial #: NSABP B-55
Principal Investigator: Dragana Tomic, MD

Learn more at Clinicaltrials.gov*

 

Study: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Clinical Trial #: NRG BR002
Principal Investigator: Christy Kesslering, MD

Learn more at Cancer.gov*


Study: Pragmatic Phase III Randomized Trial of Proton vs Photon Therapy for Patients with Non-Metastatic Breast Cancer: Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Clinical Trial #: RTOG 3510
Principal Investigator: Christy Kesslering, MD

Learn more at Clinicaltrials.gov*


Study: Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry (IMPACt)
Clinical Trial #: IMPACt
Principal Investigator: John Ayers, MD

Learn more at Clinicaltrials.gov*


Study: A Phase III Randomized Double-Blind, Placebo Controlled Study of Alpelisib in Combination with Fulvestrant for Men and Postmenopausal Women with Hormone Receptor Positive, HER2-negative Advanced Breast Cancer which Progressed on or after Aromatase Inhibitor Treatment
Clinical Trial #: SOLAR-1 (CBYL719C2301)
Principal Investigator: Perry Menini, DO

Learn more at Clinicaltrials.gov*


Study: RANDOMIZED PHASE III STUDY OF FOCAL RADIATION THERAPY FOR UNRESECTABLE, LOCALIZED INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical Trial #: NRG GI001
Principal Investigator: Nasir Mohammed, MD

Learn more at Cancer.gov*

Study: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Clinical Trial #: BB1608-303CRC
Principal Investigator: John Abad, MD

Learn more at Clinicaltrials.gov*

Study: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab, in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Clinical Trial #: E7208
Principal Investigator: Christopher George, MD

Learn more at Clinicaltrials.gov*

Study: A Prospective, Multicenter, Randomized, Open-Label, Active Controlled, Two-Parallel Group, Phase II Study to Compare the Efficacy and Safety of Masitinib to Sunitinib in Patients with Gastrointestinal Stromal Tumor After Progression with Imatinib.
Clinical Trial #: Protocol AB11002
Principal Investigator: Kevin Dawravoo, MD

Learn more at Clinicaltrials.gov*


Study: Impact of early FDG-PET directed intervention on preoperative therapy for locally advanced gastric cancer: a random assignment phase II study
Clinical Trial #: A021302
Principal Investigator: John Abad, MD

Learn more at Clinicaltrials.gov*

Study: RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA
Clinical Trial #: RTOG1112
Principal Investigator: Nasir Mohammed, MD

Learn more at Cancer.gov*

Renal

Study: Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Clinical Trial #: E2810
Principal Investigator: Robert Eisner, DO

Learn more at Cancer.gov*


Study: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Clinical Trial #: EA5142
Principal Investigator: Linda Ferris, DO

Learn more at Clinicaltrials.gov*


Study: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Clinical Trial #: NRG CC003
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov*


Study: Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer.
Clinical Trial #: LUN005-12
Principal Investigator: John Chang, MD

Learn more at Clinicaltrials.gov*


Study: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.
Clinical Trial #: Protocol S1400
Principal Investigator: Linda Ferris, DO

Learn more at Clinicaltrials.gov*


Study: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC.
Clinical Trial #: Protocol RTOG1308
Principal Investigator: Vinai Gondi, MD

Learn more at Clinicaltrials.gov*


Study: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Clinical Trial #: A151216
Principal Investigator: Linda Ferris, DO

Learn more at Cancer.gov*


Study: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Clinical Trial #: A081105
Principal Investigator: Linda Ferris, DO

Learn more at Cancer.gov*


Study: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Clinical Trial #: E4512
Principal Investigator: Linda Ferris, DO

Learn more at Cancer.gov*

Sarcoma

Study: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Clinical Trial #: ARTST1321
Principal Investigator: Robert Eisner, DO

Learn more at Clinicaltrials.gov*


NCI-MATCH: Targeted Therapy Directed By Genetic Testing In Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Study: Molecular Analysis for Therapy Choice (MATCH)
Clinical Trial #: EAY131
Principal Investigator: M. Kamran Khan, DO

Learn more at Clinicaltrials.gov*


Recurrent Tumors Previously Treated with Radiation Therapy

Study: Retreatment of non-CNS solid malignancies. Treatment sites: head & neck, thorax, pelvis, abdomen, extremities.
Clinical Trial #: UPCC 23309
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov*


Pediatric Proton Consortium Registry (PPCR)

Study: A multi-center registry of pediatric patients treated with proton radiation therapy.
Clinical Trial #: 12-103
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov*


Rare Tumors

Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Clinical Trial #: S1609
Principal Investigator: Christopher George, MD

Learn more at Clinicaltrials.gov*


Registry

Study: Evaluation tracking project: a prospective chart review of patients treated with proton therapy.
Clinical Trial #: REG001-09
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov*

Study: A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Clinical Trial #: S1505
Principal Investigator: John Abad, MD

Learn more at Clinicaltrials.gov*

Study: A Phase II-R and a Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.
Clinical Trial #: Protocol RTOG 0848
Principal Investigator: Christopher George, MD

Learn more at Clinicaltrials.gov*

Study: Quality of Life Symptoms Experienced by Children with Brain Tumors in Comparison to the National Reference.
Clinical Trial #: Protocol STU00085313
Principal Investigator: John Chang, MD

Study: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer.
Clinical Trial #: Protocol S1216
Principal Investigator: Robert Eisner, DO

Learn more at Clinicaltrials.gov*


Study: Prostate Advanced Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Clinical Trial #: PARTIQoL
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov*


Low Risk Prostate Cancer

Study: Phase III prospective randomized trial of standard fractionation vs. hypofractionation with proton radiation therapy for low risk adenocarcinoma of the prostate.
Clinical Trial #: GU002-10
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov*


Intermediate Risk Prostate Cancer

Study: Phase III study of mildly hypofractionated image guided proton beam radiation therapy with or without androgen suppression for intermediate risk adenocarcinoma of the prostate.
Clinical Trial #: GU003-10
Principal Investigator: John Chang, MD

Learn more at Clinicaltrials.gov*

Study: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision.
Clinical Trial #: Protocol N1048
Principal Investigator: Kevin Dawravoo, MD

Learn more at Clinicaltrials.gov*


Study: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Clinical Trial #: GI002
Principal Investigator: Michael Stutz, MD

Learn more at Clinicaltrials.gov*

Endometrial

Study: A Phase II Evaluation of Copanlisib (BAY 80-6946) (IND #130822), A Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Clinical Trial #: GY008
Principal Investigator: LaToya Perry, MD

Learn more at Clinicaltrials.gov*


Endometrial

Study: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin Versus Paclitaxel/Carboplatin/Placebo as initial therapy for measurable stage III or IVA, stage IVB, or Recurrent Endometrial Cancer
Clinical Trial #: GOG0286B
Principal Investigator: LaToya Perry, MD

Learn more at Clinicaltrials.gov*


Cervical

Study: RANDOMIZED PHASE III CLINICAL TRIAL OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY
Clinical Trial #: GOG0263
Principal Investigator: LaToya Perry, MD

Learn more at Cancer.gov*


Cervical

Study: Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Facial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (< 2CM) Cervical Cancer
Clinical Trial #: GOG0278
Principal Investigator: LaToya Perry, MD

Learn more at Clinicaltrials.gov*


Uterine

Study: A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus.
Clinical Trial #: GOG 0238
Principal Investigator: LaToya Perry, MD

Learn more at Clinicaltrials.gov*


Ovarian

Study: Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Clinical Trial #: NRG GY003
Principal Investigator: LaToya Perry, MD

Learn more at Clinicaltrials.gov*


Ovarian

Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Clinical Trial #: GOG 3012
Principal Investigator: LaToya Perry, MD

Learn more at Clinicaltrials.gov*


Ovarian

Study: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Clinical Trial #: NRG-GY004
Principal Investigator: Barbara Buttin, MD

Learn more at Clinicaltrials.gov*


Ovarian

Study: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Clinical Trial #: NRG-GY005
Principal Investigator: Barbara Buttin, MD

Learn more at Clinicaltrials.gov*


Ovarian

Study: A Randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer
Clinical Trial #: NRG-GY006
Principal Investigator: Barbara Buttin, MD

Learn more at Clinicaltrials.gov*


Ovarian

Study: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Clinical Trial #: GOG 3015
Principal Investigator: LaToya Perry, MD

Learn more at Clinicaltrials.gov*


Ovarian

Study: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed By Bevacizumab And Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Clinical Trial #: GOG0213
Principal Investigator: LaToya Perry, MD

Learn more at Clinicaltrials.gov*


Women's Reproductive

Study: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Clinical Trial #: GOG0225
Principal Investigator: LaToya Perry, MD

Learn more at Clinicaltrials.gov*

Current Northwestern Medicine Chicago Proton Center Clinical Trials

If you are interested in learning more about our trials, please contact your physician or visit the proton center website. If you are eligible for a proton therapy clinical trial as a patient at the Chicago Proton Center, someone from our team will likely reach out to you to communicate the details of the study.

Legal Information
*

By clicking on these websites, you are leaving the Northwestern Medicine website. These websites are independent resources. Northwestern Medicine does not operate or control the content of these websites. By visiting these websites, you agree to this third party’s terms of use for their website.